Abstract
Twenty-five patients with multiple myeloma received bone marrow grafts (n = 24) or peripheral blood stem cells (n = 1) from twin donors. The outcome was compared in a case-matched analysis to 125 patients who underwent autologous transplantation, and 125 who underwent allogeneic transplantation. Seventeen patients (68%) receiving twin transplants entered complete remission, which was not significantly different from that of autologous (48%) or allogeneic (58%) transplants. The median overall and progression-free survival for the twins was 73 and 72 months, respectively. The overall survival tended to be better (73 vs 44 months) and the progression-free survival was significantly better (72 vs 25 months) than with autologous transplantation and both were significantly better than with allogeneic transplantation. Three of 17 patients who entered complete remission following transplantation had relapsed at follow-up. This relapse rate was significantly lower than following autologous transplantation and similar to the relapse rate with allogeneic transplantation. Only two twins died of transplant-related toxicity. Six further patients died of progressive or relapsing disease. Syngeneic transplantation in multiple myeloma appears to be the treatment of choice if a twin donor is available. A lower relapse risk than in autotransplantation may be due to reinfusion of malignant cells in some patients treated with this modality or to the presence of a graft-versus-myeloma effect in some syngeneic transplants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Gahrton, G., Svensson, H., Björkstrand, B. et al. Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplant 24, 741–745 (1999). https://doi.org/10.1038/sj.bmt.1701975
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701975
Keywords
This article is cited by
-
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature
Bone Marrow Transplantation (2023)
-
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
Blood Cancer Journal (2023)
-
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
Current Hematologic Malignancy Reports (2017)
-
Reovirus as a successful ex vivo purging modality for multiple myeloma
Bone Marrow Transplantation (2014)
-
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: What Place, If Any?
Current Hematologic Malignancy Reports (2013)